Escitalopram Oxalate Tablet, Film Coated
Product Images NDC 69097-849

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Escitalopram Oxalate (NDC 69097-849). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg 90 Tab

Escitalopram Tablets USP 10 mg film-coated tablet label by Cipla USA Inc., containing 90 tablets. The label states the active ingredient escitalopram oxalate equivalent to 10 mg escitalopram per tablet. It includes storage instructions, manufacturer details (IvaGen Pharmaceuticals, Inc.), and a barcode. The label notes prescription-only status and pharmacist dispensing guidance.*

FDA Label Image

20 mg 90 Tab

Label for Escitalopram Tablets, USP 20 mg film-coated tablets by Cipla USA Inc. The label indicates 90 tablets per container, with instructions for the pharmacist to dispense the Medication Guide to patients. Storage and dispensing instructions are included, along with manufacturer and lot information, a barcode, and NDC 69097-849-05.*

FDA Label Image

5 mg 90 Tab

Label for Escitalopram Tablets, USP 5 mg by Cipla USA Inc. The film-coated tablet package contains 90 tablets. The label includes directions for pharmacists to dispense the medication guide, storage instructions, NDC 69097-847-05, and manufacturer information for InvaGen Pharmaceuticals and Cipla USA Inc.*

FDA Label Image

Str 06

Chemical structure of escitalopram oxalate, the active ingredient in Escitalopram Oxalate tablets. The diagram shows the molecular arrangement including a cyanide group, a fluorophenyl group, and an oxalate component (C2H2O4).*

FDA Label Image

Table 01

A data table titled 'Table 1' showing the difference in number of cases of suicidality per 1000 patients treated compared to placebo, categorized by age range. It indicates increased suicidality cases for patients under 18 and those aged 18-24, and decreased cases for those aged 25-64 and 65 or older.*

FDA Label Image

Table 02

A table presenting treatment-emergent adverse reactions occurring at a frequency of 2% or more and greater than placebo for Escitalopram versus placebo in patients with major depressive disorder. The table categorizes adverse reactions by body system and lists the percentage incidence for Escitalopram and placebo groups.*

FDA Label Image

Table 03

A table presenting treatment-emergent adverse reactions with Escitalopram compared to placebo in patients with Generalized Anxiety Disorder. It lists various adverse reactions by system organ class, showing the percentage of patients experiencing each reaction in both the Escitalopram (N=429) and placebo (N=427) groups.*

FDA Label Image

Table 04

A data table presenting the incidence of common adverse reactions reported in patients with major depressive disorder. The table compares the percentage of patients experiencing each adverse reaction across three groups: placebo, 10 mg/day escitalopram, and 20 mg/day escitalopram. Reactions listed include insomnia, diarrhea, dry mouth, somnolence, dizziness, increased sweating, constipation, fatigue, and indigestion.*

FDA Label Image

Table 05

A data table titled 'Incidence of Sexual Side Effects in Placebo-Controlled Clinical Trials' comparing adverse events between Escitalopram and placebo. It includes separate statistics for males and females, listing rates of ejaculatory disorder, decreased libido, impotence, and anorgasmia.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.